



Microfluidic Capture of *Mycobacterium tuberculosis* from Clinical Samples for Culture-Free Whole-Genome Sequencing

 Nabila Ismail,^a  Anzaan Dippenaar,^{a,b} George Morgan,^c Melanie Grobbelaar,^a Felicia Wells,^a Jessica Caffry,^c Cristiana Morais,^c Krzysztof Gizynski,^{c*} David McGurk,^c Eduardo Boada,^c Heather Murton,^{c§} Robin M. Warren,^a Annelies Van Rie^b

^aDivision of Molecular Biology and Human Genetics, South African Medical Research Council Centre for Tuberculosis Research, DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

^bTuberculosis Omics Research Consortium, Family Medicine and Population Health, Institute of Global Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

^cQuantuMDx Ltd., Newcastle upon Tyne, United Kingdom

Nabila Ismail and Anzaan Dippenaar contributed equally to this work. Author order was determined by the preparation of the first draft of the manuscript.

ABSTRACT *Mycobacterium tuberculosis* whole-genome sequencing (WGS) is a powerful tool as it can provide data on population diversity, drug resistance, disease transmission, and mixed infections. Successful WGS is still reliant on high concentrations of DNA obtained through *M. tuberculosis* culture. Microfluidics technology plays a valuable role in single-cell research but has not yet been assessed as a bacterial enrichment strategy for culture-free WGS of *M. tuberculosis*. In a proof-of-principle study, we evaluated the use of Capture-XT, a microfluidic lab-on-chip cleanup and pathogen concentration platform to enrich *M. tuberculosis* bacilli from clinical sputum specimens for downstream DNA extraction and WGS. Three of the four (75%) samples processed by the microfluidics application passed the library preparation quality control, compared to only one of the four (25%) samples not enriched by the microfluidics *M. tuberculosis* capture application. WGS data were of sufficient quality, with mapping depth of $\geq 25\times$ and 9 to 27% of reads mapping to the reference genome. These results suggest that microfluidics-based *M. tuberculosis* cell capture might be a promising method for *M. tuberculosis* enrichment in clinical sputum samples, which could facilitate culture-free *M. tuberculosis* WGS.

IMPORTANCE Diagnosis of tuberculosis is effective using molecular methods; however, a comprehensive characterization of the resistance profile of *Mycobacterium tuberculosis* often requires culturing and phenotypic drug susceptibility testing or culturing followed by whole-genome sequencing (WGS). The phenotypic route can take anywhere from 1 to >3 months to result, by which point the patient may have acquired additional drug resistance. The WGS route is a very attractive option; however, culturing is the rate-limiting step. In this original article, we provide proof-of-principle evidence that microfluidics-based cell capture can be used on high-bacillary-load clinical samples for culture-free WGS.

KEYWORDS *Mycobacterium tuberculosis*, tuberculosis, whole-genome sequencing, microfluidics, culture-free sequencing, cell capture

Since the characterization of the complete genome of *Mycobacterium tuberculosis* in 1998 (1), molecular biology has increasingly played a role in tuberculosis (TB) research and care. Recently, there is an increasing interest in the use of next-generation technologies, such as targeted deep sequencing and whole-genome sequencing (WGS). Targeted deep sequencing could play a role in the diagnosis of drug resistance by identifying variants in candidate resistance genes directly in sputum samples, but current assays have relatively poor performance when the sputum bacillary load is low (2). WGS has applications beyond the diagnosis of drug resistance. Since 2009, WGS has contributed to our understanding of

Editor John Osei Sekyere, University of Pretoria

Copyright © 2023 Ismail et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Nabila Ismail, nabilai@sun.ac.za.

*Present address: Krzysztof Gizynski, Lex Diagnostics, Melbourn, United Kingdom.

§Present address: Heather Murton, Lex Diagnostics, Melbourn, United Kingdom.

The authors declare a conflict of interest. GM-employed by QuantuMDx Ltd JC-employed by QuantuMDx Ltd CM-employed by QuantuMDx Ltd KG-previously employed by QuantuMDx Ltd DM-employed by QuantuMDx Ltd EB-employed by QuantuMDx Ltd HM-previously employed by QuantuMDx Ltd

Received 16 March 2023

Accepted 25 May 2023

Published 26 June 2023

TABLE 1 Comparison of library preparation and WGS data quality metrics^c

Sample no.	Bacterial load (Xpert C _T value)	Liquefaction method	Microfluidic capture	DNA concn ^b (ng/μL)	Avg library fragment size (bp)	Library concn ^a (nM)	Library prepn QC status	WGS data
1	High (14)	BD MycoPrep	Yes	0.033			Failed	
2	High (14)	BD MycoPrep	Yes	0.120	595	41.0	Passed	59× DoC; ±27% mapped reads
3	High (14)	BD MycoPrep	No	0.186			Failed	
4	High (14)	BD MycoPrep	No	0.205	601	1.4	Passed	Run failed
5	High (14)	QuantuMDx	Yes	0.042	465	10.5	Passed	25× DoC; ±9% mapped reads
6	High (14)	QuantuMDx	Yes	0.042	400	4.6	Passed	Run failed
7	High (14)	QuantuMDx	No	0.464			Failed	
8	High (14)	QuantuMDx	No	0.016			Failed	

^aLibrary concentration calculated using the formula: $\frac{\text{library concentration in } \frac{\text{ng}}{\mu\text{L}} \times 10^6}{660 \frac{\text{g}}{\text{mol}} \times \text{average fragment size}}$ with average fragment size data taken from the LabChip profile.

^bAverage concentration derived from *rpoB* quantitative PCR done in triplicate.

^cDoC, depth of coverage; QC, quality control; C_T, cycle threshold.

M. tuberculosis transmission (3), mixed infections (4), the distinction between relapse and reinfection (5), mechanisms of drug resistance (6, 7), genetic *M. tuberculosis* diversity at population level (8, 9), and within-host mycobacterial diversity (10–12). Currently, *M. tuberculosis* culture is required to obtain sufficient DNA for WGS. The culture step can reduce the true *M. tuberculosis* strain diversity present in the sputum sample, which may result in the elimination of minor populations, drug-tolerant populations, or persister subpopulations (13).

To date, most *M. tuberculosis* WGS has been performed on DNA extracted from purified subcultures. In 2015, pretreatment steps for human DNA removal and bead cleanup for enrichment of *M. tuberculosis* DNA allowed successful WGS of primary early-positive liquid cultures (14). Culture-free WGS has remained challenging as sputum is a viscous substance comprised of human cells and a plethora of microbial cells from the complex oral and lung microbiome, with often low *M. tuberculosis* representation. Brown et al. were the first to succeed in culture-free WGS employing RNA baits to selectively capture *M. tuberculosis* DNA (SureSelect; Agilent) (15), a method subsequently adopted by several other studies (13, 16–18). In 2020, Goig et al. were the first to directly sequence smear-negative sputum samples but, however, with a relatively low (55%) success rate (18). The six published culture-free *M. tuberculosis* WGS studies to date present results only on 138 predominantly smear-positive sputum samples. The varying success in obtaining sequencing data in these studies highlights the challenge of producing sequence-able *M. tuberculosis* DNA directly from a sputum sample.

The application of a technology that selectively enriches *M. tuberculosis* directly from sputum for DNA extraction could potentially increase sequence-able *M. tuberculosis* DNA without introducing culture bias. In this proof-of-concept study, we assessed the performance of Capture-XT, a microfluidic lab-on-chip cleanup and pathogen concentration technology, as a potential front end for downstream culture-free *M. tuberculosis* WGS of clinical sputum samples.

RESULTS

The amount of DNA extracted ranged from 0.033 to 0.205 ng/μL for the four BD MycoPrep-treated samples and ranged from 0.016 to 0.464 ng/μL for the four samples processed with the QuantuMDx thinning reagent (Table 1). Creation of libraries for WGS succeeded in three of the four samples that underwent microfluidic *M. tuberculosis* capture compared to one of the four samples that was not run through the microfluidics device. Samples that underwent bacterial capture had higher library concentrations (4.6, 10.5, and 41 nM) compared to the sample that was not run through the device (Table 1).

Four samples passed the WGS quality control requirements of more than 1 ng/μL and fragment size between 350 and 650 bp: sample 2 (BD MycoPrep treated, captured), sample 4 (BD MycoPrep treated, noncaptured), sample 5 (QuantuMDx treated, captured), and sample 6 (QuantuMDx treated, noncaptured) (Table 1). Due to a technical error, the sequencing run

with samples 4 and 6 failed, and no WGS data could be produced. Sample 2 (BD MycoPrep treated, captured) had a depth of coverage of $59\times$ with $\pm 27\%$ of the total number of reads mapping to the H37Rv reference genome. Sample 5 (QuantuMDx treated, captured) had a depth of coverage of $25\times$, and $\pm 9\%$ of reads mapped to the reference genome.

DISCUSSION

WGS of *M. tuberculosis* has already made invaluable contributions to tuberculosis research, but the culture step needed to obtain sufficient amounts of DNA limits its applications (19). Currently, most WGS methods are developed for sequencing on a “purified” *M. tuberculosis* subculture or on a primary liquid culture shortly after flagging positive for mycobacterial growth (14). WGS using DNA obtained from specimens without a culture enrichment step could speed up the turnaround time from sample collection to sequence results, which is essential for patient care. This would also allow the elucidation of the true population diversity that is otherwise biased by the culture process (20, 21). Bait capturing of *M. tuberculosis* DNA for culture-free WGS has not been consistently successful and adds significant costs and complexity to the sample preparation (13, 15, 17). Similarly, culture-free targeted deep sequencing methods have had limited and inconsistent success in processing smear-negative specimens (2).

Microfluidics applications to separate bacterial cells in unprocessed samples already play a valuable role in single-cell research (22). Certain microfluidic applications have incorporated cultivation and visual estimation of growth, but this is possible only for rapidly growing bacteria (23, 24). For clinical sputum samples, microfluidic applications could capture the mycobacteria and reduce the amounts of nonmycobacteria, thus enriching the *M. tuberculosis* for downstream analyses. To date, only one study has evaluated the use of a microfluidic sample preparation for *M. tuberculosis* enrichment. This study found that a low input of *M. tuberculosis* ($\sim 10,000$ cells) resulted in efficient cell concentration, lysis, and purification for downstream enrichment PCR and barcoding for whole-genome shotgun sequencing (25). This study was, however, not performed directly on a sputum sample but used aliquots of two clinical *M. tuberculosis* culture isolates (25).

Our study, the first assessing the use of microfluidic pathogen-concentration technology for *M. tuberculosis* sequencing directly from sputum, provides proof-of-principle evidence that microfluidics-based cell capture can be used for culture-free WGS. Several limitations should be considered when interpreting the results. First, the sample size of this pilot study was small, including only 8 experiments. Furthermore, one of the two sequencing runs failed and could not be repeated as all material had been used. Second, we pooled sputa for comparability purposes. The mycobacterial load of the pooled sample tested was high, with an Xpert MTB/RIF Ultra cycle threshold (C_t) value of 14 relating to a smear-positive sample with a smear grade of 2+ or 3+ (26). Further studies are thus needed to evaluate the performance of microfluidics capture on clinical sputum samples with various mycobacterial loads.

In conclusion, despite the progress in sequencing technology and bioinformatics analyses, limited progress has been made in methods to prepare clinical samples for *M. tuberculosis* WGS directly from sputum. While our data show promising results, larger studies are needed to evaluate the use of microfluidic pathogen-concentration techniques for direct sequencing of clinical sputum samples.

MATERIALS AND METHODS

Preparation of sputum samples. Sputum samples ($n = 13$) from patients residing in the Cape Town metropolitan area under evaluation for TB (University of Cape Town Human Research Ethics Committee protocol number 546/2018) were pooled, mixed using a vortex mixer to achieve sample homogeneity, and split into eight 1.5-mL aliquots. The pooled clinical sputum sample had a high mycobacterial load with an Xpert MTB/RIF Ultra (assay version 3) C_t value of 14 (performed on the GeneXpert II system), corresponding to about 10^7 CFU/mL (27). Pooling was necessary to create a homogeneous sample with a high mycobacterial load.

Sputum sample liquefaction. Two pretreatment methods were used. Four samples were processed by the standard *N*-acetyl-L-cysteine (NALC)–NaOH method which has both liquefaction and decontamination properties. Sputum pretreated with the NALC–NaOH BBL MycoPrep (Becton, Dickinson, NJ, USA) solution was incubated at room temperature for 15 min, neutralized with phosphate-buffered saline (PBS) (up to 50 mL), and centrifuged at $3,000 \times g$ for 15 min, and the supernatant was removed. The other four samples were processed using the proprietary QuantuMDx thinning reagent, which has only liquefaction properties, before

incubation for 1 h. For samples submitted for capture ($n = 2$ for each method), the pellet was then resuspended in 5 mL QuantuMDx GP buffer (10% [vol/vol] glycerol, 0.2% [vol/vol] Pluronic F68, and 0.01 M EDTA).

Mycobacterial capture. Four of the eight samples were processed using the QuantuMDx microfluidic capture device, of which two had been pretreated with BD MycoPrep and two with the QuantuMDx thinning reagent. First, samples underwent ion reduction by mixing with ion exchange resin to ensure that the conductivity of the sample was suitable for the dielectrophoresis (DEP) device. Samples were then diluted (1:10) in GP buffer and run through the microfluidic system, which was driven by positive pressure supplied by an FLPG Plus (Fluigent) and regulated using a Flow EZ (Fluigent). Capture of *M. tuberculosis* cells was performed by applying an alternating current across the electrodes, the sinusoidal waveform was produced using an arbitrary waveform generator (AFG1022; Tektronix), and the signal was amplified (9250; Tabor Electronics). After processing the sample, the current was halted and any captured cells were eluted in 50 μL of GP buffer for downstream processing.

Lysis, DNA extraction, and DNA quantification. To extract the DNA, the eight samples were treated overnight with 10 mg/mL lysozyme (Roche, Basel, Switzerland) with agitation at 37°C followed by cetyltrimethylammonium bromide (CTAB) DNA extraction (28). DNA was precipitated using isopropanol overnight, and dried DNA for each sample was resuspended in 12 μL of Tris-EDTA.

Real-time PCR quantification of the extracted DNA was performed in triplicate by amplifying the single-copy *rhoB* gene (forward primer, 5' ACG GTC GCT TCG TCG AG 3'; reverse primer, 5' GGG CAC GTA CTC CAC CTC 3') using a standard curve. Each 10- μL reaction solution comprised nuclease-free water (23.5 μL), Qiagen HotStarTaq Plus master mix (5 μL), SYTO9 (1 μL), SSO Advanced (5 μL) primer mix (0.5 μL), and DNA (1 μL). The amplification protocol consisted of an initial activation step of 95°C for 30 s, followed by 40 cycles of 95°C for 15 s and 60°C for 30 s, with a change of 1.6°C/s increments, and a melting step of 65°C for 15 s and 95°C for 15 s with a change of 0.2°C/s increments. All reactions were performed using QuantStudio 5 (Thermo Fisher Scientific).

Library preparation and quality control. The entire volume of DNA left after quantification (~9 μL) was normalized to 30 μL with nuclease-free water. The Nextera DNA Flex library prep kit (Illumina, CA, USA) was used per the manufacturer's instructions for fragmentation and postfragmentation cleanup. Amplification of fragmented DNA was done using an average of 13 PCR cycles. Library cleanup was performed with diluted sample purification beads (SPB) at a 0.5 \times bead-to-DNA ratio, followed by a second cleanup with pure SPB. The samples were washed twice using 80% ethanol. Libraries captured on the beads were eluted with an end volume of 30 μL resuspension buffer. Quantification was done with the Qubit double-stranded DNA (dsDNA) high-sensitivity (HS) assay on a Qubit 4 fluorometer (Thermo Fisher Scientific, MA, USA), and the library fragments were analyzed with a high-sensitivity LabChip assay. Thereafter, the library molarity was calculated, and libraries were pooled in equimolar concentrations.

Whole-genome sequencing and quality assessment of WGS data. Libraries with a DNA concentration of at least 1 ng/ μL and a fragment size between 350 and 650 bp were considered eligible for WGS. The library pool (2 nM) and PhiX control (10 nM) were denatured and diluted with 0.1 M NaOH, 200 mM Tris-HCl, pH 7.0, and hybridization (HT1) buffer to 20 pM. The 20 pM libraries and 20 pM PhiX (3% spike) control were combined to a final volume of 550 μL to a concentration of 1.3 pM. A thawed MiniSeq 300-cycle high-output cartridge and flow cell were loaded with 500 μL of the final 1.3 pM library spiked with 3% PhiX control.

WGS analysis was done using the XBS pipeline (29), which provides a summary of metrics to assess the overall quality of the WGS data including genome-wide depth of coverage and the percentage of reads that mapped to the *M. tuberculosis* H37Rv reference genome (NC_000962.3).

Data availability. Reads are deposited in the European Nucleotide Archive (accession number PRJEB55527).

ACKNOWLEDGMENTS

We thank K. Dheda (University of Cape Town) for allowing the use of laboratory space in which to use the QuantuMDx Ltd. prototype instrument.

This work was supported by the Research Foundation Flanders (FWO), under grant no. G0F8316N (FWO Odysseus), the National Research Foundation (NRF), the South African Medical Research Council (SAMRC), and the Stellenbosch University Faculty of Medicine Health Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NRF or the SAMRC.

Conflicts of interest: N.I., none to declare; A.D., none to declare; M.G., none to declare; F.W., none to declare; R.M.W., none to declare; A.V.R., none to declare; G.M., employed by QuantuMDx Ltd.; J.C., employed by QuantuMDx Ltd.; C.M., employed by QuantuMDx Ltd.; K.G., previously employed by QuantuMDx Ltd.; D.M., employed by QuantuMDx Ltd.; E.B., employed by QuantuMDx Ltd; H.M., previously employed by QuantuMDx Ltd.

REFERENCES

1. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaija F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393:537–544. <https://doi.org/10.1038/31159>.

2. Bonnet I, Enouf V, Morel F, Ok V, Jaffré J, Jarlier V, Aubry A, Robert J, Sougakoff W. 2021. A comprehensive evaluation of GeneLEAD VIII DNA platform combined to Deeplex Myc-TB assay to detect in 8 days drug resistance to 13 antituberculous drugs and transmission of *Mycobacterium tuberculosis* complex directly from clinical samples. *Front Cell Infect Microbiol* 11:707244. <https://doi.org/10.3389/fcimb.2021.707244>.
3. Oostvogels S, Ley SD, Heupink TH, Dippenaar A, Streicher EM, De Vos E, Meehan CJ, Dheda K, Warren R, Van Rie A. 2022. Transmission, distribution and drug resistance-conferring mutations of extensively drug-resistant tuberculosis in the Western Cape Province, South Africa. *Microb Genom* 8:000815. <https://doi.org/10.1099/mgen.0.000815>.
4. Shin SS, Modongo C, Baik Y, Allender C, Lemmer D, Colman RE, Engelthaler DM, Warren RM, Zetola NM. 2018. Mixed *Mycobacterium tuberculosis*-strain infections are associated with poor treatment outcomes among patients with newly diagnosed tuberculosis, independent of pretreatment heteroresistance. *J Infect Dis* 218:1974–1982. <https://doi.org/10.1093/infdis/jty480>.
5. Dippenaar A, De Vos M, Marx FM, Adroub SA, van Helden PD, Pain A, Sampson SL, Warren RM. 2019. Whole genome sequencing provides additional insights into recurrent tuberculosis classified as endogenous reactivation by IS6110 DNA fingerprinting. *Infect Genet Evol* 75:103948. <https://doi.org/10.1016/j.meegid.2019.103948>.
6. Beckert P, Sanchez-Padilla E, Merker M, Dreyer V, Kohl TA, Utpatel C, Köser CU, Barilar I, Ismail N, Omar SV, Klopper M, Warren RM, Hoffmann H, Maphalala G, Ardizzone E, de Jong BC, Kerschberger B, Schramm B, Andres S, Kranzer K, Maurer FP, Bonnet M, Niemann S. 2020. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. *Genome Med* 12:104. <https://doi.org/10.1186/s13073-020-00793-8>.
7. Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, Utpatel C, Cirillo DM, Rodrigues C, Nilgiriwala KS, CRyPTIC Consortium, Fowler PW, Merker M, Niemann S. 2021. Deciphering bedaquiline and clofazimine resistance in tuberculosis: an evolutionary medicine approach. *bioRxiv*. 2021.03.19.436148.
8. Ngabonziza JCS, Loiseau C, Marceau M, Jouet A, Menardo F, Tzfadia O, Antoine R, Niyigena EB, Mulders W, Fissette K, Diels M, Gaudin C, Duthoy S, Ssengooba W, André E, Kaswa MK, Habimana YM, Brites D, Afolabi D, Mazarati JB, de Jong BC, Rigouts L, Gagneux S, Meehan CJ, Supply P. 2020. A sister lineage of the *Mycobacterium tuberculosis* complex discovered in the African Great Lakes region. *Nat Commun* 11:2917. <https://doi.org/10.1038/s41467-020-16626-6>.
9. Coscolla M, Lewin A, Metzger S, Maetz-Renssing K, Calvignac-Spencer S, Nitsche A, Dabrowski PW, Radonic A, Niemann S, Parkhill J, Couacy-Hymann E, Feldman J, Comas I, Boesch C, Gagneux S, Leendertz FH. 2013. Novel *Mycobacterium tuberculosis* complex isolate from a wild chimpanzee. *Emerg Infect Dis* 19:969–976. <https://doi.org/10.3201/eid1906.121012>.
10. Ley SD, de Vos M, Van Rie A, Warren RM. 2019. Deciphering within-host microevolution of *Mycobacterium tuberculosis* through whole-genome sequencing: the phenotypic impact and way forward. *Microbiol Mol Biol Rev* 83:e00062-18. <https://doi.org/10.1128/MMBR.00062-18>.
11. Lieberman TD, Wilson D, Misra R, Xiong LL, Moodley P, Cohen T, Kishony R. 2016. Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated *Mycobacterium tuberculosis*. *Nat Med* 22:1470–1474. <https://doi.org/10.1038/nm.4205>.
12. Nimmo C, Brien K, Millard J, Grant AD, Padayatchi N, Pym AS, O'Donnell M, Goldstein R, Breuer J, Balloux F. 2020. Dynamics of within-host *Mycobacterium tuberculosis* diversity and heteroresistance during treatment. *EBioMedicine* 55:102747. <https://doi.org/10.1016/j.ebiom.2020.102747>.
13. Nimmo C, Shaw LP, Doyle R, Williams R, Brien K, Burgess C, Breuer J, Balloux F, Pym AS. 2019. Whole genome sequencing *Mycobacterium tuberculosis* directly from sputum identifies more genetic diversity than sequencing from culture. *BMC Genomics* 20:389. <https://doi.org/10.1186/s12864-019-5782-2>.
14. Votintseva AA, Pankhurst LJ, Anson LW, Morgan MR, Gascoyne-Binzi D, Walker TM, Quan TP, Wyllie DH, Del Ojo Elias C, Wilcox M, Walker AS, Peto TEA, Crook DW. 2015. Mycobacterial DNA extraction for whole-genome sequencing from early positive liquid (MGIT) cultures. *J Clin Microbiol* 53:1137–1143. <https://doi.org/10.1128/JCM.03073-14>.
15. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZM, Depledge DP, Nikolayevskyy V, Broda A, Stone MJ, Christiansen MT, Williams R, McAndrew MB, Tutilil H, Brown J, Melzer M, Rosmarin C, McHugh TD, Shorten RJ, Drobniwski F, Speight G, Breuer J. 2015. Rapid whole-genome sequencing of *Mycobacterium tuberculosis* isolates directly from clinical samples. *J Clin Microbiol* 53:2230–2237. <https://doi.org/10.1128/JCM.00486-15>.
16. Votintseva AA, Bradley P, Pankhurst L, Del Ojo Elias C, Loose M, Nilgiriwala K, Chatterjee A, Smith EG, Sanderson N, Walker TM, Morgan MR, Wyllie DH, Walker AS, Peto TEA, Crook DW, Iqbal Z. 2017. Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples. *J Clin Microbiol* 55:1285–1298. <https://doi.org/10.1128/JCM.02483-16>.
17. Doyle RM, Burgess C, Williams R, Gorton R, Booth H, Brown J, Bryant JM, Chan J, Creer D, Holdstock J, Kunst H, Lozewicz S, Platt G, Romero EY, Speight G, Tiberi S, Abubakar I, Lipman M, McHugh TD, Breuer J. 2018. Direct whole-genome sequencing of sputum accurately identifies drug-resistant *Mycobacterium tuberculosis* faster than MGIT culture sequencing. *J Clin Microbiol* 56:e00666-18. <https://doi.org/10.1128/JCM.00666-18>.
18. Goig GA, Cancino-Muñoz I, Torres-Puente M, Villamayor LM, Navarro D, Borrás R, Comas I. 2020. Whole-genome sequencing of *Mycobacterium tuberculosis* directly from clinical samples for high-resolution genomic epidemiology and drug resistance surveillance: an observational study. *Lancet Microbe* 1:e175–e183. [https://doi.org/10.1016/S2666-5247\(20\)30060-4](https://doi.org/10.1016/S2666-5247(20)30060-4).
19. Vongthilath-Moeung R, Poncet A, Renzi G, Schrenzel J, Janssens J-P. 2021. Time to detection of growth for *Mycobacterium tuberculosis* in a low incidence area. *Front Cell Infect Microbiol* 11:704169. <https://doi.org/10.3389/fcimb.2021.704169>.
20. Sanoussi CN, Afolabi D, Rigouts L, Anagonou S, de Jong B. 2017. Genotypic characterization directly applied to sputum improves the detection of *Mycobacterium africanum* West African 1, under-represented in positive cultures. *PLoS Negl Trop Dis* 11:e0005900. <https://doi.org/10.1371/journal.pntd.0005900>.
21. McNeerney R, Clark TG, Campino S, Rodrigues C, Dolinger D, Smith L, Cabibbe AM, Dheda K, Schito M. 2017. Removing the bottleneck in whole genome sequencing of *Mycobacterium tuberculosis* for rapid drug resistance analysis: a call to action. *Int J Infect Dis* 56:130–135. <https://doi.org/10.1016/j.ijid.2016.11.422>.
22. Alexandre L, Pereiro I, Bendali A, Tabnaoui S, Srbova J, Bilkova Z, Deegan S, Joshi L, Viovy JL, Malaquin L, Dupuy B, Descroix S. 2018. A microfluidic fluidized bed to capture, amplify and detect bacteria from raw samples. *Methods Cell Biol* 147:59–75. <https://doi.org/10.1016/bs.mcb.2018.07.001>.
23. Pereiro I, Bendali A, Tabnaoui S, Alexandre L, Srbova J, Bilkova Z, Deegan S, Joshi L, Viovy J-L, Malaquin L, Dupuy B, Descroix S. 2017. A new microfluidic approach for the one-step capture, amplification and label-free quantification of bacteria from raw samples. *Chem Sci* 8:1329–1336. <https://doi.org/10.1039/c6sc03880h>.
24. Kim K, Kim S, Jeon JS. 2018. Visual estimation of bacterial growth level in microfluidic culture systems. *Sensors (Basel)* 18:447. <https://doi.org/10.3390/s18020447>.
25. Kim S, De Jonghe J, Kulesa AB, Feldman D, Vatanen T, Bhattacharyya RP, Berdy B, Gomez J, Nolan J, Epstein S, Blainey PC. 2017. High-throughput automated microfluidic sample preparation for accurate microbial genomics. *Nat Commun* 8:13919. <https://doi.org/10.1038/ncomms13919>.
26. Fradejas I, Ontañón B, Muñoz-Gallego I, Ramírez-Vela MJ, López-Roa P. 2018. The value of xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. *J Clin Tuberc Other Mycobact Dis* 13:9–12. <https://doi.org/10.1016/j.jctube.2018.04.002>.
27. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG, Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM, Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D. 2017. The new Xpert MTB/RIF Ultra: improving detection of *Mycobacterium tuberculosis* and resistance to rifampin in an assay suitable for point-of-care testing. *mBio* 8:e00812-17. <https://doi.org/10.1128/mBio.00812-17>.
28. Dippenaar A, Ismail N, Grobbelaar M, Oostvogels S, de Vos M, Streicher EM, Heupink TH, van Rie A, Warren RM. 2022. Optimizing liquefaction and decontamination of sputum for DNA extraction from *Mycobacterium tuberculosis*. *Tuberculosis (Edinb)* 132:102159. <https://doi.org/10.1016/j.tube.2021.102159>.
29. Heupink TH, Verboven L, Warren RM, Van Rie A. 2021. Comprehensive and accurate genetic variant identification from contaminated and low-coverage *Mycobacterium tuberculosis* whole genome sequencing data. *Microb Genom* 7:000689. <https://doi.org/10.1099/mgen.0.000689>.